# South Korea Plasma Fractionation Market

> South Korea Plasma Fractionation Market Research Report By Product Type (Immunoglobulin, Albumin, Coagulation Factors, Protease Inhibitors), By Application (Neurology, Hematology, General Medicine, Immunology), By End User (Hospitals, Ambulatory Surgical Centers, Blood Banks, Pharmaceutical Companies) and By Technology (Centrifugation, Chromatography, Precipitation, Filtration) -Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.03%
- **2024:** $ 954.6 Million
- **2025:** $ 1,021.71 Million
- **2035:** $ 2,015.8 Million
- **Key Players:** Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company (JP), Octapharma (CH), Kedrion (IT), Biotest AG (DE), LFB Group (FR), Sangamo Therapeutics (US), Emergent BioSolutions (US)

**Report ID:** MRFR/HC/47613-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-korea-plasma-fractionation-market-49363

---

## Market Summary

## **South Korea Plasma Fractionation Market Overview**

As per MRFR analysis, the South Korea Plasma Fractionation Market Size was estimated at 567.5 (USD Million) in 2024.The South Korea Plasma Fractionation Market Industry is expected to grow from 591.5(USD Million) in 2025 to 1,050 (USD Million) by 2035. The South Korea Plasma Fractionation Market CAGR (growth rate) is expected to be around 5.356% during the forecast period (2025 - 2035).

**Key South Korea Plasma Fractionation Market Trends Highlighted**

The South Korea Plasma Fractionation Market is experiencing significant growth driven by increasing demand for immunoglobulins and albumin for therapeutic purposes. Factors such as the rise in autoimmune diseases and hemophilia cases have led to a greater need for plasma-derived therapies. The government's support in the form of policies aimed at enhancing healthcare infrastructure and investment in biotechnology is also a key driver of growth. Moreover, South Korea's aging population is pushing the demand for advanced medical treatments, including those reliant on plasma products.

Opportunities in the South Korea plasma fractionation market can be explored through the expansion of product offerings and local manufacturing capabilities.Collaborations between domestic companies and international players can enhance innovation, broaden product range, and reduce reliance on imports. Additionally, increasing funding for research and development in biotechnology could open new pathways for advancements in plasma fractionation technologies, helping to meet the rising healthcare demands of the population. Recent trends show a growing emphasis on safety and quality improvement in plasma collection and processing.

The South Korean government’s stringent regulatory framework promotes high standards in blood product manufacturing, encouraging companies to adopt advanced technologies for better efficiency and safety. These trends reflect a shift towards a more patient-centric approach in healthcare, where the quality of plasma-derived products is paramount. Additionally, the rise of personalized medicine is influencing the development of tailor-made therapies using plasma components, indicating a forward-looking trajectory for the South Korean plasma fractionation market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**South Korea Plasma Fractionation Market Drivers**

**Rising Demand for Immunoglobulin Therapies**

The South Korea Plasma Fractionation Market Industry is experiencing a surge in demand for immunoglobulin therapies, which are critical for treating various autoimmune disorders and immunodeficiencies. As per the Ministry of Health and Welfare in South Korea, the prevalence of primary immunodeficiency diseases has shown an increase of approximately 30% over the past decade, with around 8,000 affected individuals reported by 2022.

The increasing awareness about these conditions coupled with advancements in therapeutic developments by established organizations such as Green Cross Corporation and Hanall Biopharma has contributed significantly to the market growth.With the increase in healthcare access to immunoglobulin products, the South Korean Plasma Fractionation Market is expected to boom as there is an increasing concern for improving the quality of life for these individuals.

**Technological Advancements in Plasma Processing**

Technological advancements in plasma fractionation processes are driving significant growth within the South Korea Plasma Fractionation Market Industry. Innovations such as better separation technologies and enhanced purification methods not only improve yield and quality of plasma-derived products but also reduce operational costs. According to research from the Korea Health Industry Development Institute, South Korea has invested over 200 Million USD in technological upgrades in its healthcare sector in recent years.This investment has fostered the development of facilities capable of producing high-quality plasma products, ensuring compliance with international standards and strengthening South Korea's position in the global market.

**Growing Geriatric Population**

The increasing geriatric population in South Korea is another critical driver for the South Korea Plasma Fractionation Market Industry. According to Statistics Korea, by 2025, approximately 18.9% of the population is expected to be over the age of 65, marking a significant rise from 13.7% in 2019.

This demographic shift is likely to lead to a higher prevalence of chronic diseases, thereby amplifying the demand for plasma-derived therapeutic products, particularly for conditions prevalent among older adults, such as hemophilia and multiple sclerosis.Organizations like the Korea Plasma Industry Association are actively promoting awareness and education about the benefits of plasma therapies, which is anticipated to further boost market growth.

**Supportive Government Policies and Regulations**

The South Korean government's commitment to advancing healthcare innovation through supportive policies is a pivotal driver for the South Korea Plasma Fractionation Market Industry. Recent policy changes aimed at promoting biopharmaceutical research and development have facilitated collaboration between academia and industry stakeholders.

In 2021, the Ministry of Trade, Industry and Energy launched a 500 Million USD initiative to support biopharmaceuticals, including plasma products, which is expected to significantly bolster the local industry.Such government backing not only leads to an improved regulatory environment for plasma products but also drives investment into the sector, attracting major industry players to expand their operations in South Korea.

**South Korea Plasma Fractionation Market Segment Insights**

**Plasma Fractionation Market Product Type Insights**

The South Korea Plasma Fractionation Market exhibits diverse dynamics across various product types, which significantly contribute to the overall landscape of the industry. This market is characterized by a series of critical products such as Immunoglobulin, Albumin, Coagulation Factors, and Protease Inhibitors, each serving unique therapeutic needs. Immunoglobulin plays a fundamental role in enhancing immune responses, being particularly vital for individuals with immunodeficiencies. This segment has witnessed substantial growth due to rising clinical applications and increasing awareness of immune disorders among the population, often reflecting strong demand from healthcare providers and patients alike.

Albumin, another cornerstone of the Plasma Fractionation Market, is essential for volume expansion and maintaining oncotic pressure, always in demand within hospitals for various treatments, particularly in critical care settings. Given South Korea's aging population and rising incidences of chronic diseases, the importance of Albumin continues to grow as healthcare systems evolve to address increased patient needs.

Coagulation Factors are pivotal in treating bleeding disorders, which highlights their importance within the South Korean healthcare framework. The prevalence of conditions such as hemophilia necessitates robust supply chains and innovations in the production of these factors, ensuring that patients receive timely and effective treatments. This product type benefits from ongoing advancements in biotechnology, driving efficiency in production while enhancing patient outcomes.

Protease Inhibitors, while less universally recognized than the other product types, play a crucial role in managing viral infections and certain chronic diseases, indicating a significant opportunity for growth driven by ongoing research and development in this area. The emphasis on tailored therapies and personalized medicine in South Korea supports the expansion of this segment, as it aligns with the nation’s focus on advanced healthcare solutions. The intricate interplay of these product types and the evolving medical landscape highlight the comprehensive nature of the South Korea Plasma Fractionation Market.

Factors such as rising healthcare expenditure and increased government focus on biotechnology further bolster the market's potential for long-term growth, ensuring that each product type remains integral to advancing therapeutic strategies and improving public health outcomes.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Plasma Fractionation Market Application Insights**

The South Korea Plasma Fractionation Market demonstrates significant growth across its Application segment, which includes Neurology, Hematology, General Medicine, and Immunology. Neurology plays a crucial role, as plasma-derived therapies are pivotal in treating neurological disorders, enhancing patient outcomes and driving market demand. Hematology is another key application area, where plasma products are essential for treating blood disorders and managing hemophilia, owing to their life-saving potential.

General Medicine encompasses a wide range of conditions, with plasma components being vital in surgical applications and trauma care, emphasizing their importance in healthcare systems.Immunology pioneers the use of immunoglobulins for various autoimmune diseases and infections, making it a dominant area due to the rising prevalence of such conditions. The South Korea Plasma Fractionation Market is benefiting from advancements in technology and a growing focus on Research and Development, propelling the market forward. As the healthcare sector evolves, these applications are becoming integral in patient care, leading to a robust demand for plasma-derived products.

**Plasma Fractionation Market End User Insights**

The South Korea Plasma Fractionation Market demonstrates significant engagement across various End ser categories, including Hospitals, Ambulatory Surgical Centers, Blood Banks, and Pharmaceutical Companies. Hospitals constitute a major portion of this market, as they require plasma-derived products for treating various medical conditions, thus enhancing patient care and treatment options. Ambulatory Surgical Centers are also crucial as they contribute to efficiency in procedures involving plasma therapies, bringing increased accessibility to patients.Blood Banks play an essential role in the collection, processing, and distribution of plasma, facilitating a steady supply of essential components for therapeutic use.

Furthermore, Pharmaceutical Companies are critical in driving innovation within the market, emphasizing Research and Development to develop newer therapies and treatments utilizing plasma. The growing need for advanced medical treatments and personalized therapies in South Korea indicates a robust market environment. Moreover, the increasing incidence of chronic diseases and advancements in medical technology further contribute to the positive outlook of the South Korea Plasma Fractionation Market segmentation across these End ser categories.This multifaceted approach illustrates a comprehensive understanding of market dynamics and the importance of these segments in enhancing healthcare access and outcomes in South Korea.

**Plasma Fractionation Market Technology Insights**

The South Korea Plasma Fractionation Market within the Technology segment is experiencing significant advancements driven by innovation and robust healthcare infrastructure. Centrifugation is a critical process, often seen as the backbone of plasma separation, and is essential for isolating components with high purity levels, which is vital for therapeutic applications. Chromatography plays a pivotal role in ensuring the precise separation of proteins and other biomolecules, thus enhancing the efficacy of plasma-derived medicinal products.

Meanwhile, Precipitation methods provide cost-effective and scalable solutions for large-scale separation procedures, making them particularly appealing in both industrial and clinical settings.Filtration technologies are also gaining traction, owing to their ability to ensure consistent quality and safety standards in plasma processing. The overall South Korea Plasma Fractionation Market is fueled by increasing investments in Research and Development, strong regulatory support, and rising demand for immunoglobulins and other blood-derived therapies, which collectively drive the industry's growth and technological advancements. As healthcare demands evolve, these technological methods are crucial for improving patient outcomes and meeting the requirements of the ever-expanding biopharmaceutical landscape.

**South Korea Plasma Fractionation Market Key Players and Competitive Insights**

The South Korea Plasma Fractionation Market has witnessed robust growth due to rising medical needs and advancements in biopharmaceutical technologies. As the demand for plasma-derived therapies increases, the market has become a competitive landscape where various key players strive to enhance their product offerings and expand their market share. Factors such as the rising prevalence of hemophilia, immunodeficiency disorders, and other related health conditions are fueling the demand for these therapies. The competitive dynamics are influenced by the ability of companies to innovate, adhere to regulatory standards, and establish strong distribution networks.

Additionally, there is a noticeable trend towards collaborative efforts, including partnerships and alliances, aimed at expanding the capabilities of plasma fractionation technologies and improving therapeutic outcomes for patients. The competition is further accentuated by the increasing focus on cost-effective solutions and the drive for sustainability within the production processes.Octapharma has established a significant presence in the South Korea Plasma Fractionation Market by leveraging its comprehensive product range and commitment to research and development.

The company specializes in human protein therapies and offers a diverse portfolio of albumin, clotting factor concentrates, and immunoglobulins that cater to the healthcare needs of various patient populations. Octapharma's strengths lie in its state-of-the-art production facilities that adhere to global quality standards, ensuring the safety and efficacy of its products. With a dedication to continuous innovation, Octapharma has invested heavily in clinical research, which further positions the company as a leader in this sector.

The company's strong relationships with healthcare providers and stakeholders in South Korea help enhance its market presence and facilitate the accessibility of its therapies among patients in need.Biocentury Transgenics has carved out a notable niche in the South Korea Plasma Fractionation Market by focusing on innovative biopharmaceutical solutions tailored to the specific needs of the local population. The company offers a range of products, including therapeutic proteins and other advanced plasma derivatives, which are developed using proprietary technologies that maximize efficiency and therapeutic potential.

Key strengths of Biocentury Transgenics include its extensive research capabilities and strong collaborations with academic institutions and research organizations in South Korea. These partnerships facilitate innovation and accelerate the development of new therapies, catering to the increasing healthcare demands. Furthermore, the company has engaged in strategic mergers and acquisitions to enhance its capabilities and expand its product portfolio. Biocentury Transgenics demonstrates a proactive approach to meeting regulatory requirements, ensuring that its offerings are compliant and safe for use. This strategic focus not only solidifies its market presence but also reinforces its commitment to excellence within the South Korean biopharmaceutical landscape.

**Key Companies in the South Korea Plasma Fractionation Market Include**

- Octapharma
- Biocentury Transgenics
- Medytox
- Shandong Taibang Biological Products
- Hualan Biological Engineering
- Kedrion
- Takeda Pharmaceutical
- Korea National Corporation
- Green Cross Holdings
- GC Pharma
- Hanall Biopharma

**South Korea Plasma Fractionation Market Industry Developments**

The South Korea Plasma Fractionation Market has been witnessing significant developments recently. Companies such as Octapharma and GC Pharma are expanding their production capabilities in line with rising demand for immunoglobulins and other plasma-derived products. In August 2023, GC Pharma announced plans to increase its manufacturing capacity, a move prompted by the anticipated growth in global market needs. Furthermore, on a larger scale, Takeda Pharmaceutical has been actively engaging in collaborations to enhance its portfolio in biologics, especially focusing on rare diseases.

The market is also seeing strategic mergers and acquisitions; for example, in July 2023, Hualan Biological Engineering completed its acquisition of a local biotech firm to bolster its capabilities in plasma products. In 2022, Korea National Corporation initiated a partnership with Medytox to enhance R&D efforts in immunotherapy and expand its biopharmaceutical offerings. Overall, the industry's landscape is rapidly evolving with investments aimed at meeting both local and global healthcare demands, reflecting a robust growth trajectory within the South Korea Plasma Fractionation Market.

**South Korea Plasma Fractionation Market Segmentation Insights**

**Plasma Fractionation Market Product Type****Outlook**

- Immunoglobulin
- Albumin
- Coagulation Factors
- Protease Inhibitors

**Plasma Fractionation Market Application****Outlook**

- Neurology
- Hematology
- General Medicine
- Immunology

**Plasma Fractionation Market End User****Outlook**

- Hospitals
- Ambulatory Surgical Centers
- Blood Banks
- Pharmaceutical Companies

**Plasma Fractionation Market Technology****Outlook**

- Centrifugation
- Chromatography
- Precipitation
- Filtration

## Market Drivers

### Government Initiatives and Funding

Government support plays a crucial role in the development of the plasma fractionation market. In South Korea, various initiatives aimed at enhancing healthcare infrastructure and promoting research in biopharmaceuticals are underway. The government has allocated substantial funding to support research and development in this sector, which is expected to foster innovation in plasma fractionation technologies. For instance, recent budgets have earmarked millions of dollars for advancing bioprocessing capabilities. Such financial backing not only encourages local companies to invest in plasma fractionation but also attracts foreign investments, thereby expanding the market landscape.

### Rising Investment in Biopharmaceuticals

The surge in investment within the biopharmaceutical sector is a key driver for the plasma fractionation market. South Korea has emerged as a hub for biopharmaceutical research, attracting both domestic and international investors. The increasing focus on developing novel therapies and biologics has led to a rise in funding for plasma fractionation projects. Reports indicate that investments in biopharmaceuticals have grown by over 15% annually, reflecting a strong commitment to advancing this field. This influx of capital is expected to facilitate the expansion of plasma fractionation capabilities, ultimately benefiting the market.

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases in South Korea is a pivotal driver for the plasma fractionation market. Conditions such as hemophilia, immune deficiencies, and other blood-related disorders necessitate the use of plasma-derived therapies. As the population ages, the demand for these therapies is expected to grow, potentially increasing the market size significantly. Reports indicate that the prevalence of hemophilia alone is around 1 in 10,000 individuals, which translates to a substantial patient base requiring treatment. This trend suggests that healthcare providers will increasingly rely on plasma fractionation to meet therapeutic needs, thereby propelling the market forward.

### Growing Awareness of Plasma-Derived Products

There is a noticeable increase in public awareness regarding the benefits of plasma-derived products in South Korea. Educational campaigns and outreach programs have been instrumental in informing both healthcare professionals and patients about the efficacy of these therapies. This heightened awareness is likely to drive demand for plasma fractionation products, as patients become more informed about their treatment options. Market data suggests that the demand for immunoglobulins, a key product of plasma fractionation, has seen an annual growth rate of approximately 8% in recent years. This trend indicates a robust market potential as awareness continues to rise.

### Technological Innovations in Plasma Processing

Technological advancements in plasma processing are significantly influencing the plasma fractionation market. Innovations such as improved separation techniques and enhanced purification processes are leading to higher yields and better quality of plasma-derived products. In South Korea, companies are increasingly adopting automated systems and advanced bioreactors, which streamline production and reduce costs. These innovations not only improve efficiency but also ensure compliance with stringent regulatory standards. As a result, the market is likely to experience growth driven by the introduction of new technologies that enhance product offerings and operational capabilities.

## Future Outlook

The [Plasma Fractionation Market](https://www.marketresearchfuture.com/reports/plasma-fractionation-market-7397) is projected to grow at a 7.03% CAGR from 2025 to 2035, driven by increasing demand for immunoglobulins and advancements in fractionation technologies.

**New opportunities:**

- Expansion of contract manufacturing services for biopharmaceutical companies.
- Development of innovative plasma-derived therapies targeting rare diseases.
- Investment in automated plasma collection and processing technologies.

By 2035, the plasma fractionation market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Neurology (Largest) vs. Immunology (Fastest-Growing)

In the South Korea plasma fractionation market, the application segment is primarily dominated by neurology, which holds a significant share due to the increasing prevalence of neurological disorders and the growing awareness around plasma-based therapies. Hematology and general medicine follow, contributing to the total market growth but not at the same pace. Immunology, while a smaller segment, is witnessing a rapid rise in demand as immunological disorders become more recognized and targeted treatment options expand.

The growth trends within the application segment highlight neurology maintaining its lead owing to substantial investments in research and development. Meanwhile, immunology is emerging as the fastest-growing area, driven by advancing technologies and improving patient outcomes. The need for effective treatments for autoimmune conditions and allergies, coupled with rising healthcare expenditures, supports the burgeoning demand for immunological solutions in the market.

Neurology: Dominant vs. Immunology: Emerging

Neurology is the dominant application within the South Korea plasma fractionation market, benefiting from a robust foundation of research and successful therapeutic outcomes in treating various neurological conditions. This segment thrives on significant investments in healthcare advancements, leading to enhanced product offerings. On the contrary, immunology is an emerging segment characterized by rapid expansion due to a surge in awareness and diagnosis of immunological disorders. This segment capitalizes on innovative therapies that address unmet medical needs, thereby positioning itself favorably in the market. Both segments underscore the importance of plasma-derived products, with neurology focusing on established treatments and immunology paving the way for groundbreaking therapeutic interventions.

### By Product Type: Immunoglobulin (Largest) vs. Coagulation Factors (Fastest-Growing)

In the South Korea plasma fractionation market, Immunoglobulin takes the lead with substantial market share owing to its widespread applications in treating immune deficiencies and autoimmune diseases. Albumin follows, recognized for its role in volume expansion and therapy for burns and liver diseases. Coagulation Factors and Protease Inhibitors, while trailing, hold critical positions, particularly among specific patient demographics requiring targeted therapies.

Growth trends in this segment show robust momentum, especially in the Coagulation Factors, which is emerging as the fastest-growing product type. The increase can be attributed to advancements in biotechnology that enhance production efficiency and quality. Additionally, rising awareness and diagnosis of bleeding disorders are fuelling demand, while Immunoglobulin remains propelled by ongoing research into its therapeutic potentials and increasing healthcare expenditure in South Korea.

Immunoglobulin (Dominant) vs. Protease Inhibitors (Emerging)

Immunoglobulin stands out as the dominant product in the South Korea plasma fractionation market, widely utilized for its therapeutic properties in various medical conditions, including immune system disorders and infections. It is favored for its proven efficacy and established safety profile, making it a mainstay in hospitals and clinics. In contrast, Protease Inhibitors represent an emerging segment, gaining traction due to their role in treating chronic conditions such as HIV. This growing interest is driven by advancements in formulation technologies and increased investments in R&D, making Protease Inhibitors a promising area for future market growth as they address unmet medical needs.

### By End User: Hospitals (Largest) vs. Pharmaceutical Companies (Fastest-Growing)

In the South Korea plasma fractionation market, hospitals hold a substantial market share due to their extensive patient care needs and the critical application of plasma-derived products in treatment procedures. This segment continues to dominate, leveraging robust infrastructure and a high patient turnover rate to maintain its position as the leading end-user. In contrast, pharmaceutical companies are also significant players, focusing on the development of innovative therapies that utilize plasma-derived products, thus contributing to their notable market presence.

Growth trends within this segment indicate a rising demand for advanced plasma therapies, particularly in hospitals, where the need for effective treatments is increasing. Meanwhile, pharmaceutical companies are rapidly expanding their research and production capabilities to capitalize on the growing market for plasma-derived medicines, driven by increased investments in biotechnology and a focus on personalized medicine. This growth is supported by favorable regulatory environments that encourage development in the healthcare sector, making this segment dynamic and competitive.

Hospitals (Dominant) vs. Pharmaceutical Companies (Emerging)

Hospitals represent the dominant force within the South Korea plasma fractionation market, characterized by their essential role in patient care and the vast network of services they provide. Their extensive use of plasma products for various treatments positions them as key consumers within this industry. On the other hand, pharmaceutical companies are emerging as vital innovators, investing in cutting-edge research to develop new therapies and enhance existing plasma-derived products. This shift highlights a growing collaboration between healthcare providers and pharmaceutical innovators, as both sectors recognize the importance of plasma-based treatments in addressing complex health conditions and improving patient outcomes. The strategic focus on enhancing product efficacy and expanding therapeutic options is vital for sustaining future growth in these segments.

### By Technology: Centrifugation (Largest) vs. Filtration (Fastest-Growing)

In the South Korea plasma fractionation market, the segmentation by technology reveals distinct distribution patterns. Centrifugation is recognized as the largest segment, capturing a significant share due to its established reliability and efficiency in separating plasma components. In contrast, filtration is rapidly gaining traction, driven by advancements in technology that enhance purification processes, making it a valuable contender in the market.

Growth trends within this segment are primarily characterized by the increasing demand for high-quality plasma products and the need for efficient processing technologies. The rise of chronic diseases necessitates more precise and effective methods for plasma separation, thereby boosting the filtration segment. Furthermore, innovations and investments in centrifugation techniques are also driving overall market growth, creating a dynamic landscape where both technologies are evolving to meet healthcare requirements.

Technology: Centrifugation (Dominant) vs. Filtration (Emerging)

Centrifugation stands out as the dominant technology in the South Korea plasma fractionation market, primarily due to its long-standing efficacy in efficiently separating plasma from whole blood. Its ability to handle large volumes quickly and reliably is a significant advantage for healthcare providers. On the other hand, filtration is emerging as a vital technology, offering innovative solutions for the purification and concentration of plasma components. This technology utilizes membranes that facilitate selective separation, catering to the growing demand for high purity plasma derivatives. The increasing focus on product quality and safety standards in the healthcare industry is propelling filtration's adoption. Together, these technologies illustrate a comprehensive approach to plasma fractionation, aimed at meeting evolving healthcare needs.

## Competitive Benchmarking

The plasma fractionation market in South Korea is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and regional expansion. Key players such as Grifols (ES), CSL Behring (AU), and Takeda Pharmaceutical Company (JP) are at the forefront, each adopting distinct strategies to enhance their market presence. Grifols (ES) focuses on expanding its product portfolio through research and development, while CSL Behring (AU) emphasizes strategic acquisitions to bolster its capabilities in immunoglobulin therapies. Takeda Pharmaceutical Company (JP) appears to be leveraging its global footprint to enhance distribution networks, thereby increasing accessibility to its plasma-derived products. Collectively, these strategies contribute to a dynamic competitive environment, where innovation and operational efficiency are paramount.In terms of business tactics, companies are increasingly localizing manufacturing to reduce supply chain vulnerabilities and enhance responsiveness to market demands. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure fosters an environment where collaboration and strategic alliances are essential for growth, as companies seek to optimize their operations and expand their reach.

In October  Grifols (ES) announced a partnership with a local South Korean biotech firm to co-develop a new line of immunoglobulin therapies. This collaboration is strategically significant as it not only enhances Grifols' R&D capabilities but also allows for localized production, which could lead to reduced costs and improved market penetration. Such partnerships are indicative of a broader trend towards localized innovation in the plasma fractionation sector.

In September  CSL Behring (AU) completed the acquisition of a South Korean plasma collection center, a move that is likely to strengthen its supply chain and increase its capacity for plasma sourcing. This acquisition underscores the importance of vertical integration in the market, as companies aim to secure their supply chains amidst growing demand for plasma-derived therapies. The strategic importance of this acquisition lies in its potential to enhance CSL Behring's operational efficiency and market responsiveness.

In August  Takeda Pharmaceutical Company (JP) launched a new digital platform aimed at streamlining its plasma collection processes in South Korea. This initiative reflects a growing trend towards digital transformation within the industry, as companies seek to leverage technology to enhance operational efficiency and patient engagement. The strategic importance of this digital platform lies in its potential to optimize resource allocation and improve the overall patient experience, thereby positioning Takeda favorably in a competitive market.

As of November  current trends in the plasma fractionation market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, supply chain reliability, and innovative product offerings. This shift suggests that companies that prioritize R&D and operational excellence will be better positioned to thrive in an increasingly complex market.

## Recent News & Developments

The South Korea Plasma Fractionation Market has been witnessing significant developments recently. Companies such as Octapharma and GC Pharma are expanding their production capabilities in line with rising demand for immunoglobulins and other plasma-derived products. In August 2023, GC Pharma announced plans to increase its manufacturing capacity, a move prompted by the anticipated growth in global market needs. Furthermore, on a larger scale, Takeda Pharmaceutical has been actively engaging in collaborations to enhance its portfolio in biologics, especially focusing on rare diseases.

The market is also seeing strategic mergers and acquisitions; for example, in July 2023, Hualan Biological Engineering completed its acquisition of a local biotech firm to bolster its capabilities in plasma products. In 2022, Korea National Corporation initiated a partnership with Medytox to enhance R&D efforts in immunotherapy and expand its biopharmaceutical offerings. Overall, the industry's landscape is rapidly evolving with investments aimed at meeting both local and global healthcare demands, reflecting a robust growth trajectory within the South Korea Plasma Fractionation Market.

## Report Scope

| MARKET SIZE 2024 | 954.6(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1021.71(USD Million) |
| MARKET SIZE 2035 | 2015.8(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.03% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Grifols (ES), CSL Behring (AU), Takeda Pharmaceutical Company (JP), Octapharma (CH), Kedrion (IT), Biotest AG (DE), LFB Group (FR), Sangamo Therapeutics (US), Emergent BioSolutions (US) |
| Segments Covered | Application, Product Type, End User, Technology |
| Key Market Opportunities | Advancements in biopharmaceuticals drive demand for innovative plasma fractionation technologies in South Korea. |
| Key Market Dynamics | Rising demand for immunoglobulins drives innovation and competition in the plasma fractionation market. |
| Countries Covered | South Korea |

## Frequently Asked Questions

**Q: What is the current valuation of the plasma fractionation market in South Korea?**
A: The market valuation was $954.6 Million in 2024.

**Q: What is the projected market size for plasma fractionation in South Korea by 2035?**
A: The projected valuation for 2035 is $2015.8 Million.

**Q: What is the expected CAGR for the South Korea plasma fractionation market during 2025 - 2035?**
A: The expected CAGR during this period is 7.03%.

**Q: Which companies are the key players in the South Korea plasma fractionation market?**
A: Key players include Grifols, CSL Behring, Takeda Pharmaceutical Company, and Octapharma.

**Q: What are the main application segments in the South Korea plasma fractionation market?**
A: Main application segments include Neurology, Hematology, General Medicine, and Immunology.

**Q: What was the market valuation for the Immunology segment in 2024?**
A: The Immunology segment was valued at $381.84 Million in 2024.

**Q: How much is the Albumin product type projected to generate by 2035?**
A: The Albumin product type is projected to generate $550.0 Million by 2035.

**Q: What is the market size for hospitals as an end user in 2024?**
A: In 2024, hospitals accounted for a market size of $300.0 Million.

**Q: Which technology segment had a valuation of $300.0 Million in 2024?**
A: The Chromatography technology segment had a valuation of $300.0 Million in 2024.

**Q: What is the projected growth for the Coagulation Factors product type by 2035?**
A: The Coagulation Factors product type is projected to grow to $400.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-plasma-fractionation-market-49363*